Polymer-drug conjugates: Recent development in clinical oncology
| Autor: | Chun Li, Sidney Wallace |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Drug
Paclitaxel Polymers media_common.quotation_subject Drug Evaluation Preclinical Pharmaceutical Science Antineoplastic Agents Pharmacology Article chemistry.chemical_compound Therapeutic index Neoplasms Animals Humans Medicine media_common Clinical Trials as Topic Drug Carriers Polymer-drug conjugates business.industry Clinical trial Polyglutamic Acid Targeted drug delivery chemistry Nanocarriers Drug carrier business |
| Zdroj: | Advanced Drug Delivery Reviews. 60:886-898 |
| ISSN: | 0169-409X |
| DOI: | 10.1016/j.addr.2007.11.009 |
| Popis: | Targeted drug delivery aims to increase the therapeutic index by making more drug molecules available at the diseased sites while reducing systemic drug exposure. In this update, we provide an overview of polymer-drug conjugates that have advanced into the clinical trials. These systems use synthetic water-soluble polymers as the drug carriers. The preclinical pharmacology and recent data in clinical trials with poly(L-glutamic acid)-paclitaxel (PG-TXL) are discussed first. This is followed by a summary of conjugates of a variety of polymeric conjugates with chemotherapeutic agents. Results from early clinical trials of these polymer-drug conjugates have demonstrated several advantages over the corresponding parent drugs, including fewer side effects, enhanced therapeutic efficacy, ease of drug administration, and improved patient compliance. Collectively, these data warrant further clinical development of polymer-drug conjugates as a new class of anticancer agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect